International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
Leukemia · 2025-03 · 39 (3) · 543-554
DOI: 10.1038/s41375-024-02482-6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Leukemia, online erschienen am 27.01.2025. Verfasst von Luciano J Costa und 31 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. ljcosta@uabmc.edu. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Practice Guidelines as Topic. Die Arbeit wurde bisher 88-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the treatment of multiple myeloma (MM). There are several products available around the world and several more in development targeting primarily B-cell maturation antigen (BCMA) and G protein–coupled receptor class C group 5 member D (GRPC5D). The relatively rapid availability of multiple immunotherapies brings the necessity to understand how a certain agent may affect the safety and efficacy of a subsequent immunotherapy so MM physicians and patients can aim at optimal sequential use of these therapies. The International Myeloma Working Group conveyed panel of experts to review patient and disease-related factors affecting efficacy and safety of immunotherapy, summarize existing information on sequencing therapy and provide a series of core recommendations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. ljcosta@uabmc.edu.
- Division of Hematology and Oncology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Department of Oncology, McMaster University, Hamilton, ON, Canada.
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
- Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA.
Zitieren
APA
Costa, L. J., Banerjee, R., Mian, H., Weisel, K., Bal, S., Derman, B. A., Htut, M. M., Nagarajan, C., Rodriguez, C., Richter, J., Frigault, M. J., Ye, J. C., van de Donk, N. W. C. J., Voorhees, P. M., Puliafito, B., Bahlis, N., Popat, R., Chng, W. J., Ho, P. J., …, & Chari, A. (2025). International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia, 39(3), 543-554. https://doi.org/10.1038/s41375-024-02482-6
Vancouver
Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, et al. International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39(3):543-554. doi:10.1038/s41375-024-02482-6
BibTeX
@article{Costa2025,
author = {Costa, Luciano J and Banerjee, Rahul and Mian, Hira and Weisel, Katja and Bal, Susan and Derman, Benjamin A and Htut, Maung M and Nagarajan, Chandramouli and Rodriguez, Cesar and Richter, Joshua and Frigault, Matthew J and Ye, Jing C and van de Donk, Niels W C J and Voorhees, Peter M and Puliafito, Benjamin and Bahlis, Nizar and Popat, Rakesh and Chng, Wee Joo and Ho, P Joy and Kaur, Gurbakhash and Kapoor, Prashant and Du, Juan and Schjesvold, Fredrik and Berdeja, Jesus and Einsele, Hermann and Cohen, Adam D and Mikhael, Joseph and Biru, Yelak and Rajkumar, S Vincent and Lin, Yi and Martin, Thomas G and Chari, Ajai},
title = {International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma},
journal = {Leukemia},
year = {2025},
volume = {39},
number = {3},
pages = {543--554},
doi = {10.1038/s41375-024-02482-6}
}
EUVIMED